➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:


Last Updated: September 26, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,814,943

Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,814,943
Title:Apparatus and method for dispensing foam
Abstract: Apparatus for dispensing foam for the treatment of, inter alia, varicose veins. The apparatus includes a source of foam and a dispensing device which has an inlet in communication with the source of foam, a usable foam outlet, and a waste bleed outlet. The waste bleed outlet communicates with the inlet and with the useable foam outlet, and has a higher resistance to flow of foam than that of the usable foam outlet. The useable foam outlet may be blocked off such that foam may flow through the high resistance waste bleed outlet, and the usable foam outlet may be opened such that foam may flow through the usable foam outlet.
Inventor(s): Harman; Anthony David (Henley-on-thames, GB), Wright; David Dakin Iowerth (High Wycombe, GB), Mijers; Jam Willem Marinus (EH Heemstede, NL), Kay; Stuart Brian William (Ickleton, GB), Hurlstone; Christopher John (Ickleton, GB), Dixon; Julian Richard (Ickleton, GB), Pocock; Andrew Gordon (Ickleton, GB), Hogan; Brendan (Co. Galway, IE)
Assignee: BTG International Limited (London, GB)
Application Number:10/571,608
Patent Claim Types:
see list of patent claims
Device; Use;

Drugs Protected by US Patent 7,814,943

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,814,943

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0321210.7Sep 10, 2003
PCT Information
PCT FiledSeptember 09, 2004PCT Application Number:PCT/GB2004/003864
PCT Publication Date:March 17, 2005PCT Publication Number: WO2005/023678

International Family Members for US Patent 7,814,943

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 486023 ⤷  Free Forever Trial
Australia 2004270475 ⤷  Free Forever Trial
Brazil PI0414281 ⤷  Free Forever Trial
Canada 2538172 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.